Loading cancer entity…
Loading cancer entity…
Clinical trials
10,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,643)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00883623 | A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis(LEOMEX) | completed | Phase 2 | 50 | Heidelberg UniversityOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT01010295 | A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae(IELSG27) | completed | Phase 2 | 54 | International Extranodal Lymphoma Study Group (IELSG)OTHER |
| 4 |
| Nov 25, 2013 |
| clinicaltrials |
| NCT01164267 | Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL) | completed | Phase 2 | 30 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 3 | Nov 25, 2013 | clinicaltrials |
| NCT01168804 | Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma(BBD) | completed | Phase 2 | 79 | Austrian Forum Against CancerOTHER | 2 | Nov 25, 2013 | clinicaltrials |
| NCT01500161 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | terminated | Phase 2 | 1 | Texas Oncology Cancer CenterINDUSTRY | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00782379 | Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer | completed | Phase 2 | 20 | Northside Hospital, Inc.OTHER | 1 | Nov 21, 2013 | clinicaltrials |
| NCT01990144 | Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL | unknown | Phase 2 | 49 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Nov 21, 2013 | clinicaltrials |
| NCT00265889 | Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma | completed | Phase 2 | 42 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 20, 2013 | clinicaltrials |
| NCT01983761 | Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation | unknown | Phase 1 / Phase 2 | 25 | Targazyme, Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT00483262 | Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 11, 2013 | clinicaltrials |
| NCT00195871 | Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma | unknown | Phase 2 | 155 | Centre Henri BecquerelOTHER | 2 | Nov 7, 2013 | clinicaltrials |
| NCT00003885 | Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma | unknown | Phase 2 | 60 | Our Lady of Mercy Medical CenterOTHER | 1 | Nov 6, 2013 | clinicaltrials |
| NCT00006383 | Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma | completed | Phase 2 | — | Inex PharmaceuticalsINDUSTRY | 2 | Nov 6, 2013 | clinicaltrials |
| NCT01037517 | Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization | completed | Phase 2 | 52 | CancerCare ManitobaOTHER | 1 | Oct 31, 2013 | clinicaltrials |
| NCT00292695 | A Phase II Study of Nasal NK/T-cell Lymphoma | completed | Phase 2 | 33 | National Health Research Institutes, TaiwanOTHER | 1 | Oct 30, 2013 | clinicaltrials |
| NCT01361191 | Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma(R-MEGACHOP) | completed | Phase 2 | 71 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Oct 30, 2013 | clinicaltrials |
| NCT00718640 | An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function | terminated | Phase 2 | 10 | Janssen-Ortho Inc., CanadaINDUSTRY | 1 | Oct 29, 2013 | clinicaltrials |
| NCT00070187 | Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma | completed | Phase 2 / Phase 3 | 24 | Children's Oncology GroupNETWORK | 3 | Oct 17, 2013 | clinicaltrials |
| NCT00003356 | Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma | completed | Phase 1 / Phase 2 | 58 | University of RochesterOTHER | 1 | Oct 16, 2013 | clinicaltrials |
| NCT00044551 | Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 29 | BayerINDUSTRY | 6 | Oct 14, 2013 | clinicaltrials |
| NCT00079456 | Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2013 | clinicaltrials |
| NCT00058461 | Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | terminated | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00243035 | Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00100477 | Use of Topotecan in Patients With Refractory Acute Leukemia | completed | Phase 2 | 10 | US Department of Veterans AffairsFED | 1 | Sep 25, 2013 | clinicaltrials |
| NCT00002905 | Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma | unknown | Phase 2 | 20 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00003261 | Chemotherapy and Radiation Therapy in Treating Patients With HIV-Related Primary Central Nervous System Lymphoma | unknown | Phase 2 | 14 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00003262 | Combination Chemotherapy in Treating Patients With Hodgkin's Disease and HIV Infection | unknown | Phase 2 | 30 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00032149 | Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 30 | Lymphoma Trials OfficeOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00036712 | Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation | unknown | Phase 2 | 80 | Medical College of WisconsinOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00363090 | Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 84 | Toronto Sunnybrook Regional Cancer CentreOTHER | 1 | Sep 20, 2013 | clinicaltrials |
| NCT00547365 | Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction | completed | Phase 1 / Phase 2 | 10 | University of TennesseeOTHER | 1 | Sep 19, 2013 | clinicaltrials |
| NCT00002488 | Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy | unknown | Phase 2 | — | Ottawa Regional Cancer CentreOTHER | 1 | Sep 17, 2013 | clinicaltrials |
| NCT00048555 | Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 90 | BiogenINDUSTRY | 1 | Sep 16, 2013 | clinicaltrials |
| NCT00799136 | A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL(CATCH) | completed | Phase 2 | 6 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 12, 2013 | clinicaltrials |
| NCT00575406 | Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma(NHL-14) | completed | Phase 2 | 94 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Aug 30, 2013 | clinicaltrials |
| NCT00115193 | Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma | completed | Phase 2 | 77 | AmgenINDUSTRY | 0 | Aug 29, 2013 | clinicaltrials |
| NCT00072449 | Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma | terminated | Phase 2 | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2013 | clinicaltrials |
| NCT00026182 | Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 99 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00669812 | High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma | unknown | Phase 2 | 60 | Cancer Research UKOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00829205 | Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment | withdrawn | Phase 1 / Phase 2 | 0 | Cancer Research UKOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00958854 | Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma | unknown | Phase 2 | 37 | Cancer Research UKOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00974792 | Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma | unknown | Phase 2 | 150 | Cancer Research UKOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01921790 | Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Aug 22, 2013 | clinicaltrials |
| NCT01923935 | Busulfan and Melphalan Conditioning in Multiple Myeloma | unknown | Phase 2 | 105 | Chonnam National University HospitalOTHER | 1 | Aug 19, 2013 | clinicaltrials |
| NCT00005609 | Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia | completed | Phase 2 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Aug 16, 2013 | clinicaltrials |
| NCT00241371 | A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 8 | Washington University School of MedicineOTHER | 1 | Aug 13, 2013 | clinicaltrials |
| NCT01232712 | A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies | completed | Phase 1 / Phase 2 | 15 | Vaxil Therapeutics Ltd.INDUSTRY | 1 | Aug 9, 2013 | clinicaltrials |
| NCT00315757 | Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 105 | Human Genome Sciences Inc.INDUSTRY | 4 | Aug 8, 2013 | clinicaltrials |
| NCT00025064 | Combination Chemotherapy With or Without Radiation Therapy and Peripheral Stem Cell Transplant in Treating Children With Hodgkin's Lymphoma | unknown | Phase 2 | 260 | Children's Cancer and Leukaemia GroupOTHER | 2 | Aug 7, 2013 | clinicaltrials |
| NCT00094848 | Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | completed | Phase 2 | — | Human Genome Sciences Inc.INDUSTRY | 1 | Aug 2, 2013 | clinicaltrials |
Data updated 24 days agoSource updated Nov 25, 2013source: clinicaltrials